We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

70 hedge funds and large institutions have $251M invested in Progenics Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

3% less capital invested

Capital invested by funds: $258M → $251M (-$6.61M)

16% less funds holding

Funds holding: 83 → 70 (-13)

64% less call options, than puts

Call options by funds: $484K | Put options by funds: $1.33M

65% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 20

Holders
70
Holders Change
-13
Holders Change %
-15.66%
% of All Funds
2.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
23
Reduced
22
Closed
20
Calls
$484K
Puts
$1.33M
Net Calls
-$843K
Net Calls Change
-$346K

Top Buyers

Rank Fund Capital Flow
1
PFC
Phocas Financial Corp
California
+$2.75M
2
BC
Broadfin Capital
New York
+$2.29M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$545K
4
JG
Jefferies Group
New York
+$532K
5
BIT
BlackRock Institutional Trust
California
+$506K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.4M
2
HCMT
Highland Capital Management (Texas)
Texas
-$3.17M
3
Morgan Stanley
Morgan Stanley
New York
-$1.82M
4
BIM
Bogle Investment Management
Massachusetts
-$1.7M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
76
Ascend Capital
California
– -$800K -159,587 Closed
OAM
77
Oxford Asset Management
United Kingdom
– -$643K -127,856 Closed
JP Morgan Chase
78
JP Morgan Chase
New York
– -$551K -109,849 Closed
PAM
79
Paradigm Asset Management
New York
– -$269K -53,500 Closed
Jacobs Levy Equity Management
80
Jacobs Levy Equity Management
New Jersey
– -$241K -48,100 Closed
SCA
81
SAC Capital Advisors
Connecticut
– -$162K -32,206 Closed
Principal Financial Group
82
Principal Financial Group
Iowa
– -$117K -23,268 Closed
VKH
83
Virtu KCG Holdings
New York
– -$102K -20,267 Closed
SCM
84
Stevens Capital Management
Pennsylvania
– -$99K -19,785 Closed
SG Americas Securities
85
SG Americas Securities
New York
– -$84K -16,671 Closed
NCCM
86
Nine Chapters Capital Management
New Jersey
– -$61K -12,200 Closed
CCMH
87
Cornerstone Capital Management Holdings
New York
– -$43K -8,600 Closed
RFC
88
Russell Frank Company
Washington
– -$40K -7,985 Closed
Ameriprise
89
Ameriprise
Minnesota
– -$34K -6,836 Closed
TRCT
90
Tower Research Capital (TRC)
New York
– -$29K -5,687 Closed
1 2 3
4

PGNX Hedge Fund Activity: Q4 2013 in Review

70 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2013, worth a combined $251M — down 2.6% from $258M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of PGNX and 7 opened new positions — a net loss of 13 holders — while 22 trimmed existing stakes and 23 added.

The largest buyer was Phocas Financial Corp, opening a new position worth an estimated $2.75M. The largest seller was Fidelity Investments, cutting an estimated $11.4M.

  • 70 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2013, down from 83 in Q3 2013.
  • Funds reported $251M of Progenics Pharmaceuticals Inc stock for Q4 2013, down 2.6% quarter-over-quarter.
  • 7 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2013 and 20 closed out, a net change of -13 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2013 was Phocas Financial Corp, an estimated $2.75M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2013 was Fidelity Investments, an estimated $11.4M sold.

Based on aggregated 13F filings for Q4 2013.